Praxis Precision Medicines, Inc.
Financials
Valuation Metrics
Praxis Precision Medicines, Inc.'s Market Cap is $7.64B. At end of 2025 it was $6.63B. Ranked #1027 of 3,118 in US market (top 33%), #331 of 1,474 on NASDAQ (top 22%), #54 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $7.64B | US#1,027/3,118 Sec#54/265 |
| Revenue | $0.00 | US#2,858/3,118 Sec#193/265 |
| Net Income | $-339M | US—/3,118 Sec—/265 |
| Total Assets | $1.39B | US#2,295/3,118 Sec#72/265 |
| Net Assets | $1.34B | US#1,556/3,118 Sec#48/265 |
| Employees | 168 | US#2,509/3,118 Sec#134/265 |
| Value | ||
| P/B | 5.69x | US#2,349/3,118 Sec#158/265 |
| FCF Yield | -4.01% | US—/3,118 Sec—/265 |
| Profitability | ||
| ROE | -25.29% | US#2,524/3,118 Sec#106/265 |
| ROA | -24.40% | US#2,838/3,118 Sec#143/265 |
| Revenue Growth | -100.00% | US#2,725/3,118 Sec#182/265 |
| Financial Health | ||
| Debt Ratio | 3.66% | US#31/3,118 Sec#8/265 |
| Total Debt | $1M | US#2,964/3,118 Sec#240/265 |
| FCF | $-306M | US#2,848/3,118 Sec#234/265 |
| Cash | $475M | US#1,107/3,118 Sec#61/265 |
| Current Ratio | 15.73x | US#156/3,118 Sec#45/265 |
| Performance | ||
| 1Y Return | 37.80% | US#606/3,118 Sec#82/265 |
| 1M Return | -7.31% | US#1,947/3,118 Sec#127/265 |
| From 52W High | -30.25% | US#1,826/3,118 Sec#109/265 |
| 1Y MDD | -38.13% | US#1,823/3,118 Sec#105/265 |
| Trading | ||
| Volume | 256,307 shares | US#2,416/3,118 Sec#228/265 |
| Trading Value | $72M | US#990/3,118 Sec#58/265 |
| Per Share | ||
| EPS | $-12.16 | US—/3,118 Sec—/265 |
| BPS | $48.10 | US#465/3,118 Sec#9/265 |
Company Info
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.